News & Updates

Not all patients with advanced non-small-cell lung cancer (NSCLC) are eligible for platinum-based chemotherapy. Oral vinorelbine may be a valuable treatment option for frail and older patients in both first- and subsequent-line settings due to its manageable safety profile.

A 74-year-old nonsmoker and non­drinker presented to a private urologist in January 2025 with gross haematu­ria. Aside from benign prostatic hyper­plasia, he was well and physically fit. On 14 January 2025, a CT scan re­vealed a large mass measuring 5.8 cm with full-thickness infiltration into the bladder wall, consistent with clinical T3 disease. A metastatic lymph node (LN) of approximately 1.0 cm was not­ed in the left internal iliac region, with no distant metastases. 

A 77-year-old man with multiple well-controlled comorbidities, includ­ing hypertension, diabetes mellitus, benign prostatic hyperplasia (BPH) and atrial fibrillation (AF), presented with fatigue and pancytopenia on 4 November 2022, with white blood cell (WBC) count 2.69 x 10⁹/L, neutrophils 28 percent, haemoglobin (Hb) 11 g/dL and platelets 96 x 10⁹/L. He reported no other symptoms. Repeat blood test on 25 November 2022 showed wors­ening cytopenia: WBC 1.79 x 10⁹/L, neutrophils 23 percent, Hb 9.4 g/dL and platelets 78 x 10⁹/L. 

A 71-year-old woman, previously well, presented with a 3-month history of bilat­eral lower-limb rash. Initial blood test on 22 December 2023 showed leukocytosis with white blood cell (WBC) count 17.8 x 10⁹/L, haemoglobin 10.3 g/dL and plate­lets 172 x 10⁹/L. Peripheral blood analysis found 14 percent blast cells and marked monocytosis (15 percent). She was ad­mitted for further evaluation.

The emergence of FLT3 inhibitors has reshaped the management of patients with acute myeloid leukaemia (AML) with FLT3-internal tandem duplication (ITD) mutations. At an industry-sponsored symposium during The Second Asia Pacific Myeloid Forum (APMF 2026), Professor Adriano Venditti of the University of Rome Tor Vergata in Rome, Italy, discussed the evolving treatment landscape for AML, detailing pivotal results of the QuANTUM-First trial and the potential of the oral, second-generation, type 2 FLT3 inhibitor, quizartinib, to extend survival benefits across all phases of AML therapy and beyond the FLT3-ITD mutation into the wild-type (WT) setting.

An 84-year-old man presented with a 2-year history of chronic anae­mia (haemoglobin [Hb], 10–11 g/dL) in December 2024. His anaemia progres­sively worsened, with Hb dropping to a nadir of 7.5 g/dL. He reported sta­ble angina and reduced exercise tol­erance, with an ability to walk only on level ground and inability to climb stairs. His medical history included ischaemic heart disease, hypertension, hypothy­roidism, and mild cytopenia. 

Prof Axel Merseburger, Chairman of the Department of Urology at the University Hospital of Schleswig-Holstein in Lübeck, Germany, shares four metastatic hormone-sensitive prostate cancer (mHSPC) patient cases, discusses available treatment options and examines how individual characteristics determine optimal management.

Liposarcoma (LPS) is a rare malignant tumour of adipose tissue, characterized by significant heterogeneity and limited systemic treatment options, particularly in advanced stages. At an industry-sponsored symposium, Dr Herbert Loong of the Chinese University of Hong Kong reviewed advances in systemic therapies for LPS, highlighting clinical evidence supporting the use of eribulin in second-line (2L) and later settings. Dr Olivia Chen, on behalf of the Prince of Wales Hospital sarcoma group, presented a local case of LPS treated with eribulin + lenvatinib, which demonstrated durable clinical benefit over 2 years.